SONOSCAPE(SZ:300633) Cai Jing Wang·2025-04-14 02:50Core Viewpoint - The company reported a revenue decline of 5.02% to 2.014 billion yuan and a net profit decrease of 68.67% to 142 million yuan for the year 2024, attributing the downturn to industry policy factors and increased strategic investments [1][2]. Financial Performance - Total revenue for 2024 was 2,013,856,558.55 yuan, down from 2,120,251,604.73 yuan in 2023, reflecting a 5.02% year-on-year decrease [2]. - The medical device sector accounted for the entirety of the revenue, with a similar decline of 5.02% [2]. - Revenue breakdown by product showed: - Color Doppler ultrasound: 1,183,098,908.17 yuan, down 3.26% from 1,222,938,442.34 yuan - Endoscopes and related treatment instruments: 795,485,068.21 yuan, down 6.44% from 850,233,507.60 yuan - Accessories and others: 21,076,240.35 yuan, down 38.79% from 34,429,996.62 yuan - Other business income: 14,196,341.82 yuan, up 12.23% from 12,649,658.17 yuan [2]. - Domestic revenue decreased by 11.62%, while international revenue increased by 3.27% [2]. Research and Development - The company invested 47,293.27 million yuan in R&D, representing 23.48% of total revenue [4]. - The number of authorized patents increased by 11.89% to 1,035, and the company has received 304 software copyrights [4]. Product Development and Market Expansion - The company launched high-end ultrasound machines S80 and P80, marking a breakthrough in high-end ultrasound technology [4]. - In the veterinary ultrasound market, the ProPet X11 and ProPet E11 series were globally launched, leading to significant sales growth [5]. - The company’s cardiovascular products received EU MDR certification and were showcased at the EuroPCR 2024 conference, facilitating market entry into regions like Hong Kong and the Middle East [5].